From Lab to Lifesaver: How Dr. Rahmeh Othman’s Optogenetic Innovations Redefine Neuro-Immune Control of Inflammation in Inflammatory Bowel Disease

Inflammation wages a fierce battle deep within the human gut, a vital shield in rare instances, but a devastating force in most. For decades, IBD has remained medicine’s most baffling adversary, its flares erratic and its root causes largely veiled.

Now, that struggle is being reshaped by Dr Rahmeh “Ro” Othman, an award-winning biomedical scientist whose research connects the neural and immune networks —those unseen mediators that maintain the body’s delicate balance between protection and peril.

She says: “I’ve always been fascinated by how neurons and immune cells speak to one another—it feels like decoding a hidden language inside the body. When I began to realise that this conversation could actually shape how inflammation starts or stops, it completely changed my perspective on disease. I wanted to find a way to listen to that dialogue, not just through chemical signals but through actual communication between systems we used to treat separately.’’

She further adds: ‘That’s what drew me to optogenetic LED stimulation—because it enables precise modulation of neuronal and immune signals without disrupting the body’s natural rhythms. For me, it’s more than a technique; it’s a way to ask the body directly what it’s trying to communicate.”

That ability to listen—to translate cellular language into therapeutic rhythm—is precisely what has earned Dr. Othman international recognition.

From the Vision Health Research Network Excellence Award in Canada to the Kenneth Rainin Foundation Innovator Award at Harvard—where Dr. Othman conceived and led the awarded project—her career reflects a sustained trajectory of excellence, driven by innovative ideas and the respect of her peers.

Importantly, all of her innovations have been built on one core principle: inflammation does not exist in chaos, but is, in fact, a form of communication— a systemic conversation that can be mediated, rather than just muted.

At Harvard Medical School, Dr. Othman investigates how the immune and nervous systems communicate using optogenetics, which harnesses light-sensitive proteins to control nerve signals precisely. This work aligns with her overarching mission: to develop therapies that do not suppress the immune system, but instead restore it to a balanced, functional rhythm.

Building on significant recognition over the past years, her award-winning research project at the intersection of neuroimmunology is poised to set new standards for understanding, managing, and treating inflammation worldwide.

A Path Forged from Purpose

Long before the clean light of Harvard laboratories defined her scientific vision, Dr. Othman’s sense of purpose was forged in the unpredictable quiet of her childhood in Lebanon. Orphaned young and raised by her grandmother, she learned resilience not as a theory but as a survival skill.

She remembers: “Seeing my grandmother live with diabetes taught me that a chronic disease is not just a physical experience; it’s a dialogue that exists within the body. The symptoms of her illness differed day-to-day, and the unpredictability was more fascinating than it was frightening.’’

Dr. Othman further adds: ‘’With that, I understood that the body is continually trying to heal itself and is communicating in ways that we often do not recognise. That was a catalyst for me to explore physiology and immunology—because the cornerstone for assisting the body in regaining its equilibrium is really to understand these signals.”

That dialogue would become a pillar of a career characterised by precision, empathy, and an unwavering pursuit of connection.

After completing her degrees in biochemistry at the Lebanese University, Dr. Othman trained in France on septic shock physiology and later in Canada on neonatal gastrointestinal reflexes, prior to completing her Ph.D. in Physiology at the Université de Montréal.

While there, she discovered how the bradykinin B1 receptor promotes inflammation in diabetic retinopathy, a finding still driving the development of therapies that are largely non-invasive.

Dr. Sébastien Talbot, former Canada Research Chair in Neuro-Immunology, reflects: “Dr. Othman approached science like an architect. She didn’t just execute experiments—she built frameworks others could stand on. Her analysis of the kallikrein–kinin and B1R-iNOS pathways turned exploratory work into the department’s reference model for ocular inflammation. The benchmarks she created for permeability and oxidative stress became our internal standards. It’s rare for a doctoral researcher to redefine institutional methods, but her foresight reshaped how we design experiments to this day.”

Her pioneering studies, published in Frontiers in Pharmacology (2019) and Cells (2021), on the B1R–iNOS axis in diabetic retinopathy have become foundational references in inflammation research. They revealed a reversible pathway of ocular inflammation and proposed an innovative alternative to injections: anti-inflammatory eye drops that restore molecular balance without the need for invasive treatment.

In 2017, that vision earned her national recognition when the Vision Health Research Network awarded her its Excellence Award, one of only sixteen distinctions among more than 150 presentations at Canada’s premier vision-science conference. The committee of the Fonds de recherche du Québec – Santé cited her paper, “Role of iNOS and the Kinin B1 Receptor in Diabetic Retinopathy,” as an outstanding contribution to molecular neurophysiology.

That first significant recognition marked more than an academic milestone—it validated the inflammation pathway that would later expand into her neuro-immune work on intestinal disease. The following years brought invitations to major conferences, including the Vision Health Research Network symposia (2016–2017) and Gabriel L. Plaa Research Days (2017–2019), where her clarity and ingenuity earned repeated honors.

Her international debut came in 2018 at ARVO in Honolulu—the world’s largest vision-science congress—where her abstract on diabetic inflammation positioned her among global leaders in ocular immunology.

She reveals: “Sharing space with people whose work I had followed for many years was surreal. It was more than just sharing data – it was the feeling of being part of a scientific conversation that I had admired for so long. That moment confirmed for me that when we shine a light on the small findings, they can radiate outward when we do so with authentic enthusiasm.”

Together, these early awards trace the rise of a scientist who began mapping the body’s microvascular whispers and now shapes how modern medicine interprets inflammation as a unified conversation.

Her journey—from Lebanon to France, then to Montréal and Boston—illustrates her enduring belief that science is a systemic dialogue where precision meets purpose across biological systems. As she progressed from studying septic shock and respiratory issues to investigating gastroesophageal reflux in premature models, as well as exploring metabolic and inflammatory diseases affecting various organs from the retina to the gut, her commitment to this philosophy has only strengthened.

The Gut’s Hidden Conversations

At Harvard Medical School, Dr. Othman sought to gain deeper insight into inflammatory diseases, particularly in the gut, and focused on the enteric nervous system—the vast ‘second brain’ winding through the intestine, where millions of neurons communicate with immune cells every second. Within this hidden network, she observed patterns reminiscent of her work in the retina: inflammation not as random chaos, but as a breakdown in cellular communication.

Determined to listen to that conversation directly, she proposed a bold idea few had dared to attempt—using wireless optogenetic implants to stimulate gut neurons in freely moving mice.

Collaborating with leading neurophysiologists and a biomedical company in Chicago, Dr. Othman adapted a wireless optogenetic implant—initially designed for the brain—to manipulate enteric neuron activity precisely. Traditional optogenetic systems relied on wired LEDs, which risked tissue overheating and behavioural distortion. Her wireless adaptation overcomes these limitations, preserving the body’s natural rhythms while enabling unprecedented control over neuronal signalling.

She explains: “The gut is a symphony of neurons and immune cells that’s playing all the time. When one instrument goes out of tune, inflammation becomes noise the body can’t ignore. What excites me about optogenetics is that it lets us fine-tune that orchestra—to bring harmony back without shutting anything down completely. It’s not about silencing the immune system; it’s about giving it a better rhythm. That’s why I think of my work less as control and more as guidance.”

Her breakthrough culminated in the landmark 2025 Cell publication, “Enteric Neuronal Mechanosensation by Piezo1 Orchestrates Intestinal Motility and Mucosal Inflammation.”

In that study, Dr. Othman played a crucial role in conducting the in vivo experiments and colon injections, demonstrating that the mechanosensory channels that sense motion in the gut regulate the immune response, thereby fundamentally changing the way scientists perceive the mechanics of inflammation.

This paper illustrates the specific significance of her work to the field. This groundbreaking approach has revolutionised the way laboratories model neuro-immune inflammation and how clinicians now incorporate neural modulation as a treatment option. Dr. Othman’s methods demonstrated that mechanics and immunity are inextricably linked, transforming both experimental design and clinical outlook.

Her concurrent articles, published in the Journal of Allergy & Clinical Immunology (2024), extended this notion, framing the gut not as a closed organ but as a neuro-immune network.

Thinking back to that scientific bridge, she reflects: ”When our Cell paper was published, it felt like a bridge was finally built between physiology and immunology. For decades, the two areas had run parallel, and suddenly, we were showing how intertwined they were. The discovery of mechanosensory neurons that could tune immunity was a paradigm shift. It showed that mere movement or the physics governing the gut could act as a primary immune regulator.’’

Dr. Othman further adds: ‘’That was the moment that all the pieces came together; the molecular, the mechanical, the human. It proved that by listening to the body’s physical cues, one could re-conceptualise an entire way to treat disease.”

Through this work, Dr. Othman helped illuminate inflammation as a systemic dialogue—an interconnected biological conversation that spans organs and disciplines.

The Mechanics of Innovation

The research conducted by Dr. Othman uniquely brings together molecular biology, microsurgery, and translational physiology in a manner aimed at determining how neurons and immune cells co-regulate inflammation.

Her approaches merge microsurgical precision with molecular assays, such as ELISA, qPCR, and RNAscope, to monitor in real time how neural signalling reprograms immune behaviour.

The precision that now defines her optogenetic work grew from years of physiological modelling, including her early research on neonatal gastroesophageal reflux in premature lambs—experience that honed the dexterity and technical skill required to implant and manipulate micro-LED systems in living tissue

Dr. Othman’s growing body of scholarship—comprising ten peer-reviewed publications and two invited chapters—reflects not just productivity but also peer trust. Editors from Elsevier and Pharmaceuticals invited her to contribute alongside pioneers such as Dr. Bader and Dr. Leeb-Lundberg, culminating in the Elsevier chapter (2025) “Milestones and Highlights of Bradykinin.” The invitation positioned her among the very scientists whose foundational studies she once analysed during her doctoral years.

She contemplates: “The act of writing that chapter was among the few instances that allow you to stop for a moment. Early in my career, when I met Dr. Bader and Dr. Leeb-Lundberg, so being part of their team was like a dream come true. This was a reminder that science is not always a straight path, but rather a series of detours, and eventually, you meet again the people who created the paths you are now walking. The task of compressing decades of research into one story made me understand the deep interrelation of all the findings. At the same time, it made me grateful for the mentors and colleagues who were there to help me discover my own scientific voice.”

That same integrity extends into her peer-review service, where she has evaluated material for the Journal of Clinical Medicine, Tomography, and Pharmaceuticals. Her reviews, spanning neuro-immune signaling, imaging science, and translational inflammation, are known for their precision and depth.

Dr. Othman is widely recognized for her expertise as an evaluator and methodological advisor, and is consistently sought out for her insight into experimental design and interdisciplinary frameworks. Her selection by leading publishers and global research bodies underlines her position as a respected arbiter of rigor and innovation, a testament to the depth of her impact and work within her field of study.

She says, “Peer reviewing reminds me that science is a conversation and not a competition. You’re refining the truth we all depend on when you review someone else’s work. It keeps you humble and connected to the collective mission—making sure discoveries are solid enough to stand on. For me, it’s also a form of mentorship at scale; every review is a way of saying, ‘let’s make this stronger together.’ That mindset keeps the field honest and forward-looking.”

Together, her editorial and research contributions paint a portrait of a scientist equally adept behind the microscope or the manuscript—both creating and curating the next frontier.

Recognition and Reach

External recognition has followed her innovations. Dr. Othman’s research, conducted alongside Dr. Ruaidhri Jackson, contributed to projects supported by the Kenneth Rainin Foundation Innovator Awards (2022 and 2023), enabling the Harvard initiative that investigates how enteric neuron signalling influences systemic inflammation. Her leadership in designing and executing these studies has been central to advancing this cutting-edge work.

Dr. Othman says: “The prize was never solely for my research. It was a demonstration that a non-traditional concept could gain the confidence of some of the most outstanding thinkers in science. I had been hearing for a long time that it was unrealistic to use light in the treatment of inflammation. The Kenneth Rainin Foundation recognised its potential and provided it with the opportunity to grow. That recognition didn’t just validate my approach—it validated curiosity itself, the courage to test something no one else believed in yet.”

These honours reflect a pattern of sustained excellence reaching back to her earliest research years.

During her Ph.D. at the Université de Montréal, she received the Vision Health Research Network Excellence Award (2017) for her poster “Role of iNOS and the Kinin B1 Receptor in Diabetic Retinopathy.” The study—later cited as foundational in ocular inflammation research—provided the first preclinical evidence that blocking the B1R–iNOS axis could reverse diabetic retinal inflammation.

The Fonds de recherche du Québec – Santé commended her for producing one of the year’s most rigorous and translational studies in molecular neurophysiology.

Professor Réjean Couture, who directed her doctoral program, recalls: “Dr. Othman’s work changed how our department thought about inflammation. She demonstrated that the B1R-iNOS axis was not just a biochemical curiosity but a treatable driver of disease—and proved that a topical approach could achieve the same therapeutic reach as invasive procedures. The protocols she developed became our standard operating documents, adopted across labs. Beyond that, she was a mentor who brought rigour and clarity to every discussion, training a generation to think translationally. Her contributions still shape how we design and evaluate research today.”

That foundation of excellence continues at Harvard, where Dr. Othman now mentors young scientists, guiding them through the same patience and precision that once defined her own training.

She explains: “I tell my students that mentorship is empathy put into practice. Science can be brutally exacting, and so I try to be the sort of advisor I wish I had had when I was younger—someone who reminds you that progress equals patience. When a student struggles with an experiment, I see a younger version of myself trying to figure out why it didn’t work. Learning to stay curious and not defeated is the most rewarding aspect of what I do. Because one day, they’ll be the ones helping someone else through that same moment.”

The recognitions of Dr. Othman cut across continents and disciplines, weaving a narrative that is invariable: from retinal inflammation to neuro-immune modulation, from the vision labs of Canada to Harvard’s gut research hubs, exemplifying how curiosity, precision, and mentorship coalesce into impact.

Toward a New Era of Treatment

Dr. Othman’s current research pushes the boundaries of inflammation therapy by modulating the gut’s circuitry instead of suppressing its defences. What began as a theory is now being tested across multiple neuroscience and immunology labs worldwide.

Dr. Othman explains: “Our nervous system isn’t separate from our immune system—they’re partners in keeping us alive. Every sensation, every signal, carries an immune echo. When we finally start reading those echoes instead of ignoring them, we open up whole new ways to treat disease. I hope that one day we can modulate inflammation without suppressing it—by teaching the body to remember how to heal itself. It’s an idea that began as a theory but is now within reach.”

Her team is now developing non-invasive neural interfaces designed to recalibrate inflammatory responses. This concept could extend to disorders of the eye, skin, and lungs, linking her retinal discoveries to systemic innovation.

She adds, “For me, optogenetic LED stimulation has been both a tool in my experiments and a metaphor for understanding. It uncovers what is hidden and rekindles the purpose behind this work. When using it, I am not just activating cells—I am revealing patterns, possibilities, and hope. The best science is a matter of illumination, not only literally, with microscopes, but also figuratively—extending to how we see ourselves and the patients we aim to help.”

Dr. Othman began presenting her work on retinal inflammation in Montréal and now leads neuro-immune studies at Harvard, demonstrating how her persistence, creativity, and thoroughness transform molecular insights into tangible human benefits. Her concept—viewing inflammation as a form of communication rather than a defect—has evolved into a global platform that steers future therapeutics.

The name Dr. Othman, today, signifies accuracy, compassion, and creativity in neuro-immune research. She proved that the future of medicine might not be in quieting the immune system, but in helping it remember its rhythm with proper guidance, just like light.

ALSO READ TOP STORIES FROM NIGERIAN TRIBUNE